FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 658 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Lisocabtagene Maraleucel for Relapsed or Refractory Marginal Zone Lymphoma Mortality Trends for Most Cancers Remain Favourable In the EU, Although the Absolute Number of Cancer Deaths Is Not Declining Due To Population Ageing Abemaciclib Improves PFS at Six Months Among Patients with High-Grade Meningiomas Harbouring NF2 or CDK Pathway Alterations MOST POPULAR NCI-MATCH Update: More Labs, New Arms, and Initial Findings November 15, 2018 Molecular Profiling Identifies Targetable Alterations in Majority of Patients with Advanced... August 9, 2022 EMA Recommends Extension of Indications for Dostarlimab January 23, 2025 Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated... April 1, 2025 Load more HOT NEWS Understanding Serving Sizes Stealing Strategies from Cancerous T Cells May Boost Immunotherapy Cancer in My Community: Providing Free Access to Cancer Care in... Blood Test for Early Detection of Cancer: Final Study Results Support...
